Overall Section The Mutant Mouse Resource and Research Center (MMRRC) Consortium is the nation?s primary mutant mouse archive and distribution repository system. The MMRRC Consortium was established by the NIH to ensure the preservation, dissemination, and development of valuable mutant mouse strains and data generated by research scientists, and especially now plays a key role in supporting rigor and reproducibility of experimental results using model animals. The MMRRC Consortium was constituted as a trans-national regionally-distributed network of four Centers each hosting an archive and distribution repository, one of which is located at UC Davis (MMRRC-UCD), and an Informatics Coordination and Service Center (ICSC), also coincidentally located at UC Davis. In coordination with other members of the MMRRC Consortium, the MMRRC-UCD serves the needs of the nation?s biomedical research community by ensuring access to and optimizing utilization of transgenic, knockout and other genetically engineered mutant mice and related biomaterials, services, and new technologies. To do so, the MMRRC-UCD imports, verifies, maintains, and distributes mice, gene-targeted embryonic stem (ES) cells, and germplasm of genetically unique, scientifically valuable mice that are essential for contemporary translational biomedical research. The MMRRC-UCD also provide services and procedures to assist investigators using genetically-altered mice for research in numerous areas including cancer, neurodegenerative, metabolic, developmental, genetic, and other diseases. Finally, the MMRRC-UCD conducts resource-related research and develops and refines technologies, that add scientific value to submitted mutant mouse strains, and that capitalize on the power of mouse genetics for biomedical research. By submitting their mice to the MMRRC Consortium, and upon acceptance, assignment, and deposition into the MMRRC-UCD (or any of the other 3 Centers), investigators fulfill their obligation under the NIH Data and Resource Sharing Policies. In return, the MMRRC-UCD strives to preserve, protect, quality control, and provide mouse models for study by research scientists and investigators across the nation and the globe. Through surveys and feedback from our users, discussions with our MMRRC Consortium colleagues and NIH Program representatives, input from our Internal Advisors, and engagement with the MMRRC External Advisory Committee (EAC) of experts, the long-term sustainability and relevance of the MMRRC-UCD to the biomedical research will be assured for years to come.

Public Health Relevance

Overall Section The Mutant Mouse Resource and Research Center (MMRRC) at UC Davis (MMRRC-UCD) is the flagship of the MMRRC Consortim, and serves a leading role in facilitating research by identifying, acquiring, evaluating, characterizing, cryopreserving, and distributing mutant mouse strains to qualified biomedical investigators. The MMRRC-UCD ensures that scientifically valuable transgenic, knockout, and other genetically-engineered mutant mice and related biomaterials of human disease, development, and behavioral abnormalities are maintained for investigational use across the biomedical scientific community. The MMRRC-UCD provides expertise, infrastructure, resources and services to preserve mouse strains in perpetuity, protect them from catastrophic loss, avoid genetic and phenotypic drift, prevent pathogenic contamination and disease, and conduct resource-related research to advance the study of mutant mice as models of human disease, including cancer. The MMRRC-UCD fosters and promotes the discovery of new diagnostics, treatments, and prevention strategies against human diseases, including cancer, optimizes reproducibility of studies, and assures scientific rigor and transparency.

National Institute of Health (NIH)
Office of The Director, National Institutes of Health (OD)
Animal (Mammalian and Nonmammalian) Model, and Animal and Biological Materials Resource Cooperative Agreements (U42)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Mirochnitchenko, Oleg
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Davis
Schools of Medicine
United States
Zip Code
McCullough, Kenneth M; Daskalakis, Nikolaos P; Gafford, Georgette et al. (2018) Cell-type-specific interrogation of CeA Drd2 neurons to identify targets for pharmacological modulation of fear extinction. Transl Psychiatry 8:164
Ralvenius, William T; Neumann, Elena; Pagani, Martina et al. (2018) Itch suppression in mice and dogs by modulation of spinal ?2 and ?3GABAA receptors. Nat Commun 9:3230
Hunter, Diana V; Smaila, Brittney D; Lopes, Douglas M et al. (2018) Advillin Is Expressed in All Adult Neural Crest-Derived Neurons. eNeuro 5:
Chen, Li; Chen, Ruju; Kemper, Sherri et al. (2018) Therapeutic effects of serum extracellular vesicles in liver fibrosis. J Extracell Vesicles 7:1461505
Park, Kyung-Ran; Kim, Eun-Cheol; Hong, Jin Tae et al. (2018) Dysregulation of 5-hydroxytryptamine 6 receptor accelerates maturation of bone-resorbing osteoclasts and induces bone loss. Theranostics 8:3087-3098
Ferré, Sergi; Bonaventura, Jordi; Zhu, Wendy et al. (2018) Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A2A-Dopamine D2 Receptor Heterotetramers and Adenylyl Cyclase. Front Pharmacol 9:243
Elsegeiny, Waleed; Zheng, Mingquan; Eddens, Taylor et al. (2018) Murine models of Pneumocystis infection recapitulate human primary immune disorders. JCI Insight 3:
Noristani, Harun Najib; They, Laetitia; Perrin, Florence Evelyne (2018) C57BL/6 and Swiss Webster Mice Display Differences in Mobility, Gliosis, Microcavity Formation and Lesion Volume After Severe Spinal Cord Injury. Front Cell Neurosci 12:173
Seelige, Ruth; Saddawi-Konefka, Robert; Adams, Nicholas M et al. (2018) Interleukin-17D and Nrf2 mediate initial innate immune cell recruitment and restrict MCMV infection. Sci Rep 8:13670
Zoccal, Karina F; Gardinassi, Luiz G; Sorgi, Carlos A et al. (2018) CD36 Shunts Eicosanoid Metabolism to Repress CD14 Licensed Interleukin-1? Release and Inflammation. Front Immunol 9:890

Showing the most recent 10 out of 97 publications